Citron Martin
Amgen Inc., Department of Neuroscience, M/S 29-2-B, One Amgen Center Drive, Thousand Oaks, California 91320, USA.
Nat Neurosci. 2002 Nov;5 Suppl:1055-7. doi: 10.1038/nn940.
Alzheimer's disease is the single biggest unmet medical need in neurology. Current drugs are safe, but of limited benefit to most patients. This review discusses the scientific basis and current status of promising disease-modifying therapies in the discovery and development stages. I describe the major targets of anti-amyloid therapy and the main focus of disease modification approaches. In addition, two new potential treatment approaches supported by retrospective epidemiology are outlined.
阿尔茨海默病是神经病学中尚未满足的最大医疗需求。目前的药物是安全的,但对大多数患者益处有限。本综述讨论了处于发现和开发阶段的有前景的疾病修饰疗法的科学依据和现状。我描述了抗淀粉样蛋白疗法的主要靶点以及疾病修饰方法的主要重点。此外,还概述了两项有回顾性流行病学支持的新的潜在治疗方法。